Cargando…

Intramuscular neridronate for the treatment of complex regional pain syndrome type 1: a randomized, double-blind, placebo-controlled study

BACKGROUND: Complex regional pain syndrome type-1 (CRPS-1) is a severely disabling painful disease challenging to treat. This multicenter, randomized, double-blind placebo-controlled trial examined the efficacy of intramuscular (i.m.) neridronate in CRPS-1 patients. METHODS: A total of 78 patients d...

Descripción completa

Detalles Bibliográficos
Autores principales: Varenna, Massimo, Braga, Vania, Gatti, Davide, Iolascon, Giovanni, Frediani, Bruno, Zucchi, Francesca, Crotti, Chiara, Nannipieri, Fabrizio, Rossini, Maurizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202309/
https://www.ncbi.nlm.nih.gov/pubmed/34178124
http://dx.doi.org/10.1177/1759720X211014020
_version_ 1783707955190824960
author Varenna, Massimo
Braga, Vania
Gatti, Davide
Iolascon, Giovanni
Frediani, Bruno
Zucchi, Francesca
Crotti, Chiara
Nannipieri, Fabrizio
Rossini, Maurizio
author_facet Varenna, Massimo
Braga, Vania
Gatti, Davide
Iolascon, Giovanni
Frediani, Bruno
Zucchi, Francesca
Crotti, Chiara
Nannipieri, Fabrizio
Rossini, Maurizio
author_sort Varenna, Massimo
collection PubMed
description BACKGROUND: Complex regional pain syndrome type-1 (CRPS-1) is a severely disabling painful disease challenging to treat. This multicenter, randomized, double-blind placebo-controlled trial examined the efficacy of intramuscular (i.m.) neridronate in CRPS-1 patients. METHODS: A total of 78 patients diagnosed with CRPS-1 (aged 59.5 ± 10.3, 66.7% female) were randomly assigned to 25 mg (i.m.) neridronate (N = 41) given once daily for 16 consecutive days or placebo control (N = 37). Efficacy was assessed after 30 days using a visual analogue scale (VAS) pain score and the number of patients achieving ⩾50% reduction in VAS score. Change in clinical signs and symptoms, quality of life (QoL) using Short Form Health Survey (SF-36) and the McGill Pain Questionnaire were also assessed. RESULTS: After 30 days, VAS score decreased significantly to a greater extent in neridronate-treated patients versus placebo (31.9 ± 23.3 mm versus 52.3 ± 27.8 mm, p = 0.0003). Furthermore, the proportion of patients achieving a VAS reduction of ⩾50% was greater in the neridronate group (65.9% versus 29.7%, p = 0.0017). Clinical signs and symptoms were improved significantly in the neridronate group versus placebo for edema (72.5% versus 79.9%, p = 0.03), pain during motion (70% versus 83.3%, p = 0.0009), allodynia (20% versus 63.3%, p = 0.0004), and hyperalgesia (20% versus 56.7%, p = 0.0023). Whereas no difference was observed for QoL measures using the SF-36 questionnaire, three of the four pain variables using the McGill Pain Questionnaire improved significantly in the neridronate group. No serious drug-related adverse events were reported during the study. CONCLUSION: In patients with acute CRPS-1, i.m. injections of 25 mg neridronate were associated with clinically relevant benefit compared with placebo controls. TRIAL REGISTRATION: EU Clinical Trials Register: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001156-28
format Online
Article
Text
id pubmed-8202309
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-82023092021-06-24 Intramuscular neridronate for the treatment of complex regional pain syndrome type 1: a randomized, double-blind, placebo-controlled study Varenna, Massimo Braga, Vania Gatti, Davide Iolascon, Giovanni Frediani, Bruno Zucchi, Francesca Crotti, Chiara Nannipieri, Fabrizio Rossini, Maurizio Ther Adv Musculoskelet Dis Original Research BACKGROUND: Complex regional pain syndrome type-1 (CRPS-1) is a severely disabling painful disease challenging to treat. This multicenter, randomized, double-blind placebo-controlled trial examined the efficacy of intramuscular (i.m.) neridronate in CRPS-1 patients. METHODS: A total of 78 patients diagnosed with CRPS-1 (aged 59.5 ± 10.3, 66.7% female) were randomly assigned to 25 mg (i.m.) neridronate (N = 41) given once daily for 16 consecutive days or placebo control (N = 37). Efficacy was assessed after 30 days using a visual analogue scale (VAS) pain score and the number of patients achieving ⩾50% reduction in VAS score. Change in clinical signs and symptoms, quality of life (QoL) using Short Form Health Survey (SF-36) and the McGill Pain Questionnaire were also assessed. RESULTS: After 30 days, VAS score decreased significantly to a greater extent in neridronate-treated patients versus placebo (31.9 ± 23.3 mm versus 52.3 ± 27.8 mm, p = 0.0003). Furthermore, the proportion of patients achieving a VAS reduction of ⩾50% was greater in the neridronate group (65.9% versus 29.7%, p = 0.0017). Clinical signs and symptoms were improved significantly in the neridronate group versus placebo for edema (72.5% versus 79.9%, p = 0.03), pain during motion (70% versus 83.3%, p = 0.0009), allodynia (20% versus 63.3%, p = 0.0004), and hyperalgesia (20% versus 56.7%, p = 0.0023). Whereas no difference was observed for QoL measures using the SF-36 questionnaire, three of the four pain variables using the McGill Pain Questionnaire improved significantly in the neridronate group. No serious drug-related adverse events were reported during the study. CONCLUSION: In patients with acute CRPS-1, i.m. injections of 25 mg neridronate were associated with clinically relevant benefit compared with placebo controls. TRIAL REGISTRATION: EU Clinical Trials Register: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-001156-28 SAGE Publications 2021-06-11 /pmc/articles/PMC8202309/ /pubmed/34178124 http://dx.doi.org/10.1177/1759720X211014020 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Varenna, Massimo
Braga, Vania
Gatti, Davide
Iolascon, Giovanni
Frediani, Bruno
Zucchi, Francesca
Crotti, Chiara
Nannipieri, Fabrizio
Rossini, Maurizio
Intramuscular neridronate for the treatment of complex regional pain syndrome type 1: a randomized, double-blind, placebo-controlled study
title Intramuscular neridronate for the treatment of complex regional pain syndrome type 1: a randomized, double-blind, placebo-controlled study
title_full Intramuscular neridronate for the treatment of complex regional pain syndrome type 1: a randomized, double-blind, placebo-controlled study
title_fullStr Intramuscular neridronate for the treatment of complex regional pain syndrome type 1: a randomized, double-blind, placebo-controlled study
title_full_unstemmed Intramuscular neridronate for the treatment of complex regional pain syndrome type 1: a randomized, double-blind, placebo-controlled study
title_short Intramuscular neridronate for the treatment of complex regional pain syndrome type 1: a randomized, double-blind, placebo-controlled study
title_sort intramuscular neridronate for the treatment of complex regional pain syndrome type 1: a randomized, double-blind, placebo-controlled study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202309/
https://www.ncbi.nlm.nih.gov/pubmed/34178124
http://dx.doi.org/10.1177/1759720X211014020
work_keys_str_mv AT varennamassimo intramuscularneridronateforthetreatmentofcomplexregionalpainsyndrometype1arandomizeddoubleblindplacebocontrolledstudy
AT bragavania intramuscularneridronateforthetreatmentofcomplexregionalpainsyndrometype1arandomizeddoubleblindplacebocontrolledstudy
AT gattidavide intramuscularneridronateforthetreatmentofcomplexregionalpainsyndrometype1arandomizeddoubleblindplacebocontrolledstudy
AT iolascongiovanni intramuscularneridronateforthetreatmentofcomplexregionalpainsyndrometype1arandomizeddoubleblindplacebocontrolledstudy
AT fredianibruno intramuscularneridronateforthetreatmentofcomplexregionalpainsyndrometype1arandomizeddoubleblindplacebocontrolledstudy
AT zucchifrancesca intramuscularneridronateforthetreatmentofcomplexregionalpainsyndrometype1arandomizeddoubleblindplacebocontrolledstudy
AT crottichiara intramuscularneridronateforthetreatmentofcomplexregionalpainsyndrometype1arandomizeddoubleblindplacebocontrolledstudy
AT nannipierifabrizio intramuscularneridronateforthetreatmentofcomplexregionalpainsyndrometype1arandomizeddoubleblindplacebocontrolledstudy
AT rossinimaurizio intramuscularneridronateforthetreatmentofcomplexregionalpainsyndrometype1arandomizeddoubleblindplacebocontrolledstudy